Please assess the completion status of the following clinical trial:

Trial Title: Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA~* At least one BCC tumor (greater than 4 mm in diameter) at any skin location, to be biopsied and surgically removed.~* Had at least one liver function test \[eg, aspartate aminotransferase (AST), alanine aminotransferase (ALT)\] with normal results in the last year.~* Consent to research use of their BCC tissue.~* Cohort A or B: Willing to take itraconazole during the 2 to 3 weeks between biopsy and surgical removal of BCC~EXCLUSION CRITERIA~* History or current hepatitis or other liver disease.~* Currently taking systemic medications that would affect BCC tumors (oral retinoids) or metabolism of itraconazole (anti-convulsants, corticosteroids)~* History or current evidence of malabsorption or liver disease within the one year prior to enrollment.~* History or current evidence of hyperthyroidism increasing metabolism of itraconazole~* Unable to attend to 2nd study visit at Stanford for Mohs surgical excision~* Current immunosuppression disease (cancer, autoimmune disease)~* Receiving immunosuppressive drugs~* Pregnant~* Lactating~* Any female actively trying to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A - Itraconazole 400 mg (Type: EXPERIMENTAL): Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
- Cohort B - Itraconazole 200 mg (Type: EXPERIMENTAL): Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
- Untreated Control (Type: NO_INTERVENTION): Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).